Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7020322 in Healthy Subjects and Chronic Hepatitis B Patients
NCT02604355Phase 1Terminated
- Sponsor
- Roche
- Start
- Nov 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of RO7020322 in Chronic Hepatitis B (CHB) (4 arms), sponsored by Roche. Primary endpoints: Number of participants with adverse events up to 8 weeks, Intensity of adverse events up to 8 weeks and 3 more. Started Nov 2015; status: terminated.
02
Drugs
RO7020322
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02604355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02604355.